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Objective: The development of antibiotic resistance has
recently been recognized as a global health problem.
This study was designed to develop new potent mole-
cules that are economic and minimally toxic. The
research examined a novel one-step synthetic proce-
dure of bioactive 3-arylazo-substituted coumarin de-
rivatives (4ie4v) and further evaluated their biological
actions.
Methods: Male and female Wistar rats of appropriate
age weighing 180e200 g were used to assess the wound
incision, wound excision, acute toxicity and 1,1-
diphenyl-2-picrylhydrazyl (DPPH) models. The syn-
thesized compounds were structurally interpreted
with Differential Screening Calorimetry (DSC),
FT/IR, 1H Nuclear Magnetic Resonance (NMR),
LC-MS, UV-Visible and elemental analysis. The syn-
thesized compounds were screened to investigate their
in vitro antimicrobial, antioxidant and wound healing
activities.
Results: A series of 4-hydroxy-3-(arylazo) coumarin (4ie
4v) analogues were synthesized by coupling five different
aryl diazonium salts with 4-HC in the presence of a 10%
NaOH solution. The majority of the compounds showed
significant antimicrobial, wound healing and antioxidant
properties. The most potent compounds identified in the
analysis were 4iv and 4e.
Conclusion: This study justifies that both aryl and hetero
arylazo analogues of 4-hydroxy coumarin possess sig-
nificant antimicrobial, wound healing and antioxidant
properties.nder the CC BY-NC-ND license (http://creativecommons.org/
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C-3 aryl-substituted 4-HC is essential for broad biological
actions, such as anti-viral,1 anti-bacterial,2 anticancer,3
anticoagulant1 and antioxidant4 activities. Heteroarylazo-
substituted compounds have been widely used due to their
excellent thermal,5 optical6 and biological properties
includes antibacterial,7 antiviral8 and antioxidant9
activities. The insertion of an aryl/heteroarylazo moiety at
the C-3 position of coumarin has been reported to elicit
good antimicrobial activity.10 The 4-hydroxy 3-heteroaryl
coumarin moiety is found in many natural and synthetic
products and also exerts significant biological actions.11 In
our earlier work, we have reported the synthesis and
characterization of several novel bioactive hetero aryl-
conjugated 4-HC analogues and investigated their antimi-
crobial activity against four different bacterial pathogens.12
Subsequently, we evaluated the antimicrobial, wound
healing and antioxidant activities of earlier reported
molecules as well as those of recently developed new aryl-
conjugated 4-HC analogues against a wide range ofFigure 1: Synthesis of azo derived 4bacterial and fungal strains and confirmed their structural
characterization.
Materials and Methods
The chemicals used in this study were of synthetic grade
and were obtained from Merck specialties Ltd. (Mumbai,
India). The synthesized products were structurally confirmed
with FT/IR (JASCO FT/IR 4100 Spectrophotometer using
KBr disc), 1H NMR (Bruker H1NMR 400MHZ) using TMS
as an internal standard, LC-MS (Shimadzu-Mass spec-
trometer). differential scanning calorimetry (METTLER
TOLEDO STARe system at a heating rate of 10 C min1,
temperature range 30e350 C using aluminium cans cali-
brated with indium) and UV spectrophotometry (JASCO V-
630 Spectrophotometer). An elemental analysis was carried
out with a Perkin Elmer-2400 CHNO/S analyser system. The
melting points were determined with the open capillary
method (Elico) and are uncorrected.
4-hydroxy-3-(aryl substituted -2-yldiazenyl)-2H-chromen-
2-one (4ie4v) was synthesized as described previously12
(Figure 1).
4-((4-hydroxy-2-oxo-2H-chromen-3-yl) diazenyl)
benzenesulfonic acid, (4i)
IR (K Br) cm1: 3446 (OeH str), 2996 (AreH), 1695 (C]
O str. lactone carbonyl), 1612 (C]C str. of coumarin), 1510
(eN]N-), 1300, 1134 (SO2 str.), 1197 (C-Ostr.), 831 (1, 4
disubst. Ar); 1H NMR (DMSO-d6) d: 7.81 (d, coumarin H-5,-Hydroxy Coumarin analogues.
Table 1: Physical characteristic data of newly synthesized 4-HC aryl analogues (4ie4v).
Comps. Ar M. formula m/z Rf m. p.(C) Colour Yield (%)
4i phenyl 4-sulfonic acid C15H10N2O6S 346.03 0.8 200e210 Bright Yellow 89
4ii 2-methoxyphenyl C16H12N2O4 296.08 0.8 190e200 Coffee red 95
4iii 4- carboxy phenyl C16H10N2O5 310.06 0.8 280e290 Bright Yellow 92
4iv 3-nitrophenyl C15H9N3O5 311.05 0.9 200e210 Buff Yellow 95
4v 2-methyl phenyl C16H12N2O3 280.08 0.8 160e170 Dark Brown 87
Biological evaluation and spectral characterization of 4-HC analogues308J¼ 8.1 Hz), 7.75e7.85 (m, 4H, AreH), 7.42 (d, coumarin H-
8, J¼ 8.1 Hz), 7.37e7.65 (m, coumarin H-6 & 7); LC-MS (%
area); 92.21; m/z; 344.96 (M2); Analysis calcd % for
C15H10N2O6S: C, 52.02; H, 2.91; N, 8.09; S, 9.26 Found %:
C, 52.03; H, 2.89; N, 8.12; S,9.28.
4-hydroxy-3-(2-methoxyphenyl) diazenyl)-2H-chromen-2-
one, (4ii)
IR (K Br) cm1: 3477 (OeH str), 3021 (AreH), 2925
(CH2str. of OCH3), 1745 (C]O str. lactone carbonyl),
1608 (C]C str. of coumarin), 1505 (eN]N-), 1483, 1110
(¼CeOeCH3 str.), 1264 (C-Ostr.), 750 (1, 2 disubst. Ar);
1H NMR (DMSO-d6) d: 16.81 (s,1H,4-enolic OH), 8.09 (d,
coumarin H-5, J ¼ 8.1 Hz), 7.57 (d, coumarin H-8,
J ¼ 8.1 Hz), 7.46e7.65 (m, coumarin H-6 & 7), 6.94e7.34
(m, 4H, AreH), 3.83 (s, 3H, Ar-OCH3); LC-MS (% area);Figure 2: 1H NMR o
Figure 3: FT/IR of60.04; m/z; 296.99 (Mþ 1); Analysis calcd % for
C16H12N2O4: C, 64.86; H, 4.08; N, 9.46 Found %: C,
64.87; H, 4.11; N, 9.45.
4-((4-hydroxy-2-oxo-2H-chromen-3-yl) diazenyl) benzoic
acid, (4iii)
IR (K Br) cm1: 3446 (OeH str), 2987 (AreH), 1742 (C]
O str. of carboxylic acid), 1697 (C]O str. lactone carbonyl),
1609 (C]C str. Of coumarin), 1509 (eN]Ne), 1280 (OH
bend. / C-Ostr.), 833 (1, 4 disubst. Ar); 1H NMR (DMSO-d6)
d: 16.85 (s, 1H, 4-enolic OH), 7.84(d, coumarinH-5,
J ¼ 8.1 Hz), 7.54e8.21 (m, 4H, AreH), 7.47 (d, coumarin
H-8, J ¼ 8.1 Hz), 7.42e7.67 (m, coumarinH-6 & 7); LC-MS
(% area); 58.74; m/z; 310.95 (Mþ) Analysis calcd% for
C16H10N2O5: C, 61.94; H, 3.25; N, 9.03. Found%: C, 61.93;
H, 3.23; N, 9.05.f compound 4ii.
compound 4i.
Table 2: Electronic absorption spectral data (l max) nm of newly synthesized 4-HC aryl analogues (4ie4v).
Comps. l max (Acetonitrile) l max (Methanol) l max (DMF) l max (Dioxane) l max (DMSO) l max (THF)
4i 426 420 306, 427 390, 429 430 e
4ii 304, 445 450 435 305, 447 438 303, 448
4iii 302, 417 420 273, 405 257, 420 304, 421 285, 294, 421
4iv 254, 393 417 283, 387 255, 404 393 397
4v 429 430 284, 431 270, 303, 430 304, 432 303, 430
Figure 4: LC-MS of compound 4iv.
Figure 6: Thermogram of 4i by DSC.
Figure 5: Solvatochromism of compounds (4ie4v, 4ae4g) using 1, 4- dioxane.
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one, (4iv)
IR (K Br) cm1: 3555 (OeH str), 3088 (AreH), 1687 (C]
O str. lactone carbonyl), 1618 (C]C str. of coumarin), 1508
(eN]Ne/NO2 str.), 1271 C-Ostr.), 743 (1, 3 disubst. Ar);
1H
NMR (DMSO-d6) d: 7.83 (d, coumarin H-5, J ¼ 8.1 Hz),
7.71e8.37 (m, 4H, AreH), 7.38e7.71 (m, coumarin H-6 & 7),
7.34 (d, coumarin H-8, J¼ 8.1 Hz); LC-MS (% area); 100.00;Table 3.1: Zone of inhibition (mm) of newly synthesized 4-HC ary
strains (Mean ± S.D.).
Compd E. coli a S. ser. typhib S. typhimurium c S
Mean  S.D. Mean  S.D Mean  S.D M
4i 11.33  0.82 8.00  0.63 11.33  1.75 8
4ii 13.33  0.52 15.00  1.67 10.33  0.52 18
4iii 15.33  1.37 9.17  0.75 10.50  2.07 10
4iv 17.50  1.23 14.33  1.37 10.50  2.51 13
4v 15.50  0.55 12.00  0.00 15.33  2.16 10
4a 16.00  0.89 11.50  2.07 18.17  0.41 11
4b 18.00  2.10 10.50  2.26 10.33  2.25 10
4c 13.00  1.67 8.50  0.84 12.17  0.98 9
4d 19.00  1.27 11.50  0.84 14.17  0.75 13
4e 18.00  2.10 15.50  0.55 13.50  0.55 16
4f e e 11.17  0.98 e
4g e 10.83  1.33 12.50  1.64 11
RA 22.50  1.98 15.33  1.86 12.83  0.98 17
Total 13.81  6.66 10.94  4.19 12.53  2.65 11
ANOVA
’p’ value
0 0 0 0
Compounds
K. pneumoniae h M. luteus i B. circulans j S
Mean  S.D. Mean  S.D. Mean  S.D. M
4i e e 11.00  1.27 1
4ii 14.33  0.82 9.33  1.37 15.33  1.86 1
4iii e 11.33  1.37 14.33  1.37 1
4iv 18.50  0.55 18.33  1.37 35.50  1.23 2
4v e 10.17  0.41 17.50  2.51 e
4a 11.83  2.23 11.33  1.86 12.50  1.23 1
4b 13.50  1.23 e 11.50  1.23 1
4c e e e e
4d 12.50  0.55 11.50  1.23 e 1
4e 26.50  0.55 18.50  0.55 20.17  0.98 2
4f e 11.50  0.55 e 1
4g 12.50  1.38 11.50  0.55 12.50  0.55 1
RA 21.33  1.51 15.67  1.51 23.00  4.00 1
Total 10.08  8.96 9.94  6.22 13.33  9.78 1
ANOVA
’p’ value
0 0 0 0
e No zone of inhibition.
a Escherichia coli.
b Salmonella enterica ser. typhi.
c Salmonella enterica typhimurium.
d Salmonella enterica paratyphi.
e Shigella flexneri.
f Pseudomonas aeruginosa.
g Vibrio cholera.
h Klebsiella pneumonia.
i Micrococcus luteus.
j Bacillus circulans.
k Streptococcus mitis.
l Pectobacterium carotovorum.
m Bacillus subtilis.
n Staphylococcus aureus.m/z; 310.33 (M1); Analysis calcd % for C15H9N3O5: C,
57.88;H, 2.91; N, 13.50. Found%:C, 57.85;H, 2.92; N, 13.48.
4-hydroxy-3-(o-tolyldiazenyl)-2H-chromen-2-one, (4v)
IR (K Br) cm1: 3023 (AreH), 2925 (CH2str. of CH3),
1709 (C]O str. lactone carbonyl), 1607 (C]C str. of
coumarin), 1511 (eN]Ne), 1286 (C-Ostr.), 770 (1, 2 dis-
ubst. Ar); 1H NMR (DMSO-d6) d: 16.73 (s, 1H, 4-enolicl and heteroarylazo analogues (4ie4v, 4ae4g) against bacterial
. paratyphi d S. flexneri e P. aeruginosa f V. cholera g
ean  S.D Mean  S.D. Mean  S.D. Mean  S.D
.67  0.52 11.33  1.51 18.17  0.98 16.33  1.86
.33  1.03 e 11.33  0.82 11.67  0.82
.33  2.58 13.33  1.63 8.33  0.52 9.33  1.75
.33  3.93 19.33  0.52 19.50  1.23 16.50  2.07
.00  1.27 12.50  0.55 17.33  0.52 11.33  1.03
.50  0.55 11.50  2.81 15.00  1.41 13.00  0.63
.83  1.47 14.50  0.55 24.00  0.63 8.83  0.41
.50  1.23 13.33  0.52 18.00  0.89 e
.33  0.52 12.50  2.81 17.83  1.84 12.33  1.03
.50  1.38 24.50  0.55 18.00  1.27 19.83  0.75
11.50  2.07 17.33  0.52 8.83  0.41
.50  0.55 12.50  0.55 8.00  0.89 12.50  3.39
.83  0.75 19.50  2.07 20.67  1.51 19.83  1.33
.67  4.78 13.56  5.69 16.42  4.62 12.33  5.27
0 0 0
. mitis k P. carotovarum l B. subtilis m S. aureus n
ean  S.D. Mean  S.D Mean  S.D Mean  S.D
2.17  1.33 8.33  0.52 12.33  0.52 e
4.83  1.17 14.33  1.03 13.00  0.89 10.67  0.82
7.33  1.37 12.33  1.37 10.33  1.63 10.17  2.04
5.17  0.75 17.50  0.55 15.33  1.37 e
12.17  1.33 11.33  0.82 10.67  1.75
1.50  1.64 11.17  2.48 20.00  0.89 22.00  0.63
3.50  0.55 13.17  0.98 15.00  0.63 21.83  2.14
11.50  1.98 10.00  1.27 e
1.50  1.98 13.50  2.95 20.00  0.89 23.00  1.67
5.17  1.60 14.50  1.23 23.00  0.89 25.00  0.89
1.50  0.55 14.50  1.64 9.67  1.03 24.00  0.63
0.50  0.55 12.50  0.55 11.00  0.89 10.00  1.41
7.67  1.75 20.33  2.50 20.33  2.07 22.00  1.67
3.14  7.42 13.53  3.25 14.72  4.60 13.79  9.47
0 0 0
Table 3.2: Zone of inhibition (mm) of newly synthesized 4-HC aryl and heteroarylazo analogues (4ie4v, 4ae4g) against bacterial strains (Mean difference ± S.E.M).
Compound E. coli a S. ser. typhi b S. typhimerium c S. paratyphi d S. flexneri e P. aeruginosa f V. cholera g
(I) (J) Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value
4i RA 11.17  0.76 1.000 7.33  0.75 1.000 1.50  0.88 1.000 9.17  0.91 1.000 8.17  0.89 1.000 2.50  0.62 1.000 3.50  0.85 1.000
4ii RA 9.17  0.76 1.000 0.33  0.75 0.976 2.50  0.88 1.000 0.50  0.91 0.769 e 1 9.33  0.62 1.000 8.17  0.85 1.000
4iii RA 7.17  0.76 1.000 6.17  0.75 1.000 2.33  0.88 1.000 7.50  0.91 1.000 6.17  0.89 1.000 12.33  0.62 1.000 10.50  0.85 1.000
4iv RA 5.00  0.76 1.000 1.00  0.75 0.999 2.33  0.88 1.000 4.50  0.91 1.000 0.17  0.89 0.952 1.17  0.62 1.000 3.33  0.85 1.000
4v RA 7.00  0.76 1.000 3.33  0.75 1.000 2.50  0.88* 0.026 7.83  0.91 1.000 7.00  0.89 1.000 3.33  0.62 1.000 8.50  0.85 1.000
4a RA 6.50  0.76 1.000 3.83  0.75 1.000 5.33  0.88* 0 6.33  0.91 1.000 8.00  0.89 1.000 5.67  0.62 1.000 6.83  0.85 1.000
4b RA 4.50  0.76 1.000 4.83  0.75 1.000 2.50  0.88 1.000 7.00  0.91 1.000 5.00  0.89 1.000 3.33  0.62* 0 11.00  0.85 1.000
4c RA 9.50  0.76 1.000 6.83  0.75 1.000 0.67  0.88 0.991 8.33  0.91 1.000 6.17  0.89 1.000 2.67  0.62 1.000 e 1
4d RA 3.50  0.76 1.000 3.83  0.75 1.000 1.33  0.88 0.331 4.50  0.91 1.000 7.00  0.89 1.000 2.83  0.62 1.000 7.50  0.85 1.000
4e RA 4.50  0.76 1.000 0.17  0.75 0.875 0.67  0.88 0.685 1.33  0.91 0.999 5.00  0.89* 0 2.67  0.62 1.000 0.00  0.85 0.923
4f RA e 1 e 1 1.67  0.88 1.000 e 1 8.00  0.89 1.000 3.33  0.62 1.000 11.00  0.85 1.000
4g RA e 1 4.50  0.75 1.000 0.33  0.88 0.971 6.33  0.91 1.000 7.00  0.89 1.000 12.67  0.62 1.000 7.33  0.85 1.000
Compound K. pneumoniae h M. luteus i B. circulans j S. mitis k P. carotovarum l B. subtilis m S. aureus n
(I) (J) Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.M
p’ value Mean
(IeJ)  S.E.
P’ value Mean
(IeJ)  S.E.M
P’ value
4i RA e 1 e 1 12.00  0.95 1.000 5.50  0.69 1.000 12.00  0.96 1.000 8.00  0.66 1.000 e 1
4ii RA 7.00  0.56 1.000 6.33  0.60 1.000 7.67  0.95 1.000 2.83  0.69 1.000 6.00  0.96 1.000 7.33  0.66 1.000 11.33  0.75 1.000
4iii RA e 1 4.33  0.60 1.000 8.67  0.95 1.000 0.33  0.69 0.979 8.00  0.96 1.000 10.00  0.66 1.000 11.83  0.75 1.000
4iv RA 2.83  0.56 1.000 2.67  0.60* 0 12.50  0.95* 0 7.50  0.69* 0 2.83  0.96 1.000 5.00  0.66 1.000 e 1
4v RA e 1 5.50  0.60 1.000 5.50  0.95 1.000 e 1 8.17  0.96 1.000 9.00  0.66 1.000 11.33  0.75 1.000
4a RA 9.50  0.56 1.000 4.33  0.60 1.000 10.50  0.95 1.000 6.17  0.69 1.000 9.17  0.96 1.000 0.33  0.66 0.980 0.00  0.75 0.923
4b RA 7.83  0.56 1.000 e 1 11.50  0.95 1.000 4.17  0.69 1.000 7.17  0.96 1.000 5.33  0.66 1.000 0.17  0.75 0.956
4c RA e 1 e 1 e 1 e 1 8.83  0.96 1.000 10.33  0.66 1.000 e 1
4d RA 8.83  0.56 1.000 4.17  0.60 1.000 e 1 6.17  0.69 1.000 6.83  0.96 1.000 0.33  0.66 0.980 1.00  0.75 0.408
4e RA 5.17  0.56* 0 2.83  0.60* 0 2.83  0.95 1.000 7.50  0.69* 0 5.83  0.96 1.000 2.67  0.66* 0.001 3.00  0.75* 0.001
4f RA e 1 4.17  0.60 1.000 e 1 6.17  0.69 1.000 5.83  0.96 1.000 10.67  0.66 1.000 2.00  0.75* 0.038
4g RA 8.83  0.56 1.000 4.17  0.60 1.000 10.50  0.95 1.000 7.17  0.69 1.000 7.83  0.96 1.000 9.33  0.66 1.000 12.00  0.75 1
I¼ Test compound, J ¼ RA (Reference antibiotic), S.E.M. ¼ standard Error Mean (n ¼ 6), *p value<0.05, e No zone of inhibition.
a Escherichia coli.
b Salmonella enterica ser. typhi.
c Salmonella enterica typhimurium.
d Salmonella enterica paratyphi.
e Shigella flexneri.
f Pseudomonas aeruginosa.
g Vibrio cholera.
h Klebsiella pneumonia.
i Micrococcus luteus.
j Bacillus circulans.
k Streptococcus mitis.
l Pectobacterium carotovorum.
m Bacillus subtilis.
n Staphylococcus aureus.
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Biological evaluation and spectral characterization of 4-HC analogues312OH), 7.81(d, coumarin H-5, J ¼ 8.1 Hz), 7.47 (d, coumarin
H-8, J ¼ 8.1 Hz), 7.37e7.73 (m, coumarin H-6 &7), 6.89e
7.26 (m, 4H, AreH), 2.43 (s, 3H, Ar-CH3); LC-MS (% area);
87.63; m/z; 281.13 (Mþ 1); Analysis calcd % for
C16H12N2O3: C, 68.56; H, 4.32; N, 9.99 Found %: C, 68.57;
H, 4.31; N, 9.97.
Antimicrobial activity
The antimicrobial activities of the newly synthesized 4-HC
analogues were investigated using different microbial strains,
i.e., Escherichia coli (MTCC 614), Salmonella enterica ser.
typhi (MTCC 773), S. enterica typhimurium (MTCC 98), S.
enterica paratyphi (MTCC 3220), Shigella flexneri (MTCC
1457), Pseudomonas aeruginosa (MTCC 1035), Vibrio cholera
(MTCC 3906), Klebsiella pneumonia (MTCC 109), Micro-
coccus luteus (MTCC 1809), Bacillus circulans (MTCC 490),
Streptococcus mitis (MTCC 2695), Pectobacterium car-
otovorum (MTCC 1428), Aspergillus niger (MTCC 9933),
Candida albicans (MTCC 3017), Candida glabrata, Crypto-
coccus neoformans and Trichophyton rubrum, which were
procured from the Institute of Microbial Technology and
Gene bank, Chandigarh, India. Staphylococcus aureus and
Bacillus subtilis strain hswx8813 were isolated at the
Department of Pharmaceutical Biotechnology, Utkal
University. Freshly sub-cultured microorganisms were
used. Ampicillin and Fluconazole were used as reference
antibiotics.
The antimicrobial activity of the novel 4-HC analogues
(4ie4v and earlier reported 4ae4g) was assessed with the well
and plate method using molten nutrient agar (antibacterial)
and Sabouraud dextrose agar (antifungal).14 After
solidification, the media were inoculated, and 6-mm diam-
eter wells were punched into the media. The wells were filled
with a stock solution of test and reference compounds
(1 mgmL1) and incubated for 24 h and 72 h for the bacterial
and fungal strains, respectively, at 37 C. The diameter of theTable 4.1: Zone of inhibition (mm) of newly synthesized 4-HC aryl an
(Mean ± S.D.).
Compounds A. nigera T. rubrumb
4i 25.50  0.55 12.17  0.75
4ii 25.00  0.63 15.17  0.75
4iii 22.00  1.27 18.17  0.41
4iv 30.00  1.79 15.00  0.63
4v 25.17  0.75 12.17  1.17
4a 27.00  0.89 10.00  1.27
4b 22.17  1.17 10.83  0.98
4c 16.17  0.41 16.17  0.75
4d 21.17  1.17 10.83  0.75
4e 25.00  1.41 13.17  0.98
4f 29.33  1.63 14.50  2.51
4g 27.33  0.82 12.00  0.63
RA 19.67  1.51 17.00  0.63
Total 24.27  3.94 13.63  2.67
RA (Reference Antibiotic).
a Aspergillus niger.
b Trichophyton rubrum.
c Candida albicans.
d Candida glabrata.
e Cryptococcus neoformans.zone of inhibition was measured using the Hi-Antibiotic
Zone Scale.
Determination of minimum inhibitory concentration
(MIC)15
A 1 mgmL1 stock solution of synthesized compounds
and reference antibiotic was prepared in 10% DMF.
Furthermore, five different concentrations of (500e
31.25 mgml1) were prepared by serial dilution. The different
concentrations of respective compounds were loaded into the
wells and incubated at 37 C for 18e24 h. The MIC was
determined after incubation.
Pharmacological activity
Animals
Male and female Wistar rats of appropriate age weighing
180e200 g were used in this study. The experiments were
carried under the guidelines of the Committee for the Pur-
pose of Control and Supervision of Experiments on Animals
and approved by the Institutional Animal Ethical Commit-
tee with registration number 1171/C/08/CPCSEA and
Ref. No. 60/SPS/IAEC/SOAU.
Acute toxicity study
An acute oral toxicity study was performed on female
Wistar rats to establish the safe dose of the synthesized com-
pounds. OECD guideline No. 420 (2000) for the Acute Oral
Toxicity-Fixed Dose Procedure was followed (sighting study
andmain study) for a period of 14 days to study the acute toxic
symptoms and the behavioural changes of the animals.
Excision wound model
The test compound showing significant antimicrobial
activity against a maximum number of bacterial strains was
selected for evaluation of wound healing activity. A woundd heteroarylazo analogues (4ie4v, 4ae4g) against fungal strains
C. albicansc C. glabratad C. neoformanse
20.50  1.38 15.67  1.03 27.00  0.89
17.33  0.52 13.50  0.55 30.17  0.75
16.17  0.98 13.17  0.75 30.17  1.84
22.00  0.89 13.00  1.79 32.00  0.89
18.00  0.89 13.17  0.98 30.17  0.75
23.00  0.89 18.00  1.27 30.00  1.41
24.00  1.79 13.00  2.10 15.33  0.52
11.17  0.75 13.33  1.03 26.50  1.23
17.83  0.75 13.17  0.75 23.83  0.41
21.00  1.27 12.00  0.89 35.00  1.27
24.17  0.75 12.83  2.32 31.50  0.84
16.00  1.79 12.00  0.89 27.33  1.03
25.83  1.17 19.00  1.41 29.50  1.05
19.77  4.13 13.99  2.45 28.35  4.75
J. Sahoo and P. Sudhir Kumar 313excision model was employed using male Wistar rats to
assess the wound healing activity.16 Group-1 served as the
control, group-2 was treated with 2% w/w nitrofurazone
cream (standard) and remaining groups (group 3e10) were
topically treated with 5% and 10% w/w ointments contain-
ing test compounds once per day for 16 days. The area of the
wounds was recorded on the 4th, 8th, 12th and 16th day, and
the closing percentage and % inhibition were calculated.
Incision wound model
Light incisions were made by cutting the skin of the
Wistar rats under mild anaesthesia.17 The parted skin was
stitched together with black silk at both ends of the
incisions. The test samples were applied as above. The
tensile strength was measured with a tensiometer, 16 days
after wounding.
Antioxidant activity assay by DPPH model
The free radical scavenging activity of the novel 4-HC
analogues (4ie4v and 4ae4g) was measured using the
DPPH method with some modification.14 The antioxidant
activity of synthesized compounds was compared with that
of standard butylated hydroxytoluene. The optical density
was measured at 517 nm, and the inhibition concentration
was calculated. Solution of DPPH in methanol were used
as a control.
% of inhibition ¼ ½ðAcont AtestÞ=Atest  100
Acont ¼ absorbance of control
Atest ¼ Absorbance of the test compound.Statistical analysis
The observed zone of inhibition data were subjected to a
one way analysis of variance. The mean zone of inhibition forTable 4.2: Zone of inhibition (mm) of newly synthesized 4-HC aryl an
strains (Mean difference±S.E.M.).
Compd. A. nigera T. rubrumb C. albica
(I) Mean (IeJ) 
S.E.
p’
value
Mean (IeJ) 
S.E.M
p’
value
Mean (Ie
S.E.M
4i 5.83  0.67* 0.000 4.83  0.62 1.000 5.33 
4ii 5.33  0.67* 0.000 1.83  0.62 1.000 8.50 
4iii 2.33  0.67* 0.004 1.17  0.62 0.188 9.67 
4iv 10.33  0.67* 0.000 2.00  0.62 1.000 3.83 
4v 5.50  0.67* 0.000 4.83  0.62 1.000 7.83 
4a 7.33  0.67* 0.000 7.00  0.62 1.000 2.83 
4b 2.50  0.67* 0.002 6.17  0.62 1.000 1.83 
4c 3.50  0.67 1.000 0.83  0.62 0.999 14.67 
4d 1.50  0.67 0.098 6.17  0.62 1.000 8.00 
4e 5.33  0.67* 0.000 3.83  0.62 1.000 4.83 
4f 9.67  0.67* 0.000 2.50  0.62 1.000 1.67 
4g 7.67  0.67* 0.000 5.00  0.62 1.000 9.83 
I¼ Test compound, J ¼ RA (RA) Reference Antibiotic, S.E.M. ¼ Sta
RA (Reference Antibiotic).
a Aspergillus niger.
b Trichophyton rubrum.
c Candida albicans.
d Candida glabrata.
e Cryptococcus neoformans.each compound and each strain was compared with the
reference antibiotic with a Dunnett post hoc test. Signifi-
cance was tested at the 5% level of a type one error. The null
hypothesis was a zone of inhibition for the test compound
that was larger than that of the reference antibiotic.
Sample size determination
A minimum sample size of five was calculated based on a
probability of type 1 error (d) ¼ 0.05, Power (1  b) ¼ 0.8,
Number of groups 13 within group SD ¼ 2. However, a
sample size of six was used in the study for each compound
and each strain.
Results
Chemistry
Spectral analysis
A series of 4-hydroxy-3-(arylazo) coumarin analogues
(4ie4v) were synthesized by coupling five different aryl dia-
zonium salts to 4-HC in the presence of a 10% NaOH so-
lution (Figure 1). Diazotization was carried out in presences
of nitrosyl chloride, and any excess nitrous acid was removed
via the addition of urea. The crude products were
recrystallized from ethanol. The infrared spectra of the
prepared starting material (3) showed a strong absorption
band at 3417 cm1 corresponding to eOH group and band
at 1698 cm1 corresponding to the lactone carbonyl moiety
of 4-HC. The involved coupling reactions that initially
generated strong aryl diazonium electrophiles from different
aryl amines then ultimately coupled at the C-3 position of 4-
hydroxy coumarin to produce the desired 3-aryl azohydroxy
coumarin. The physical data of the prepared compounds are
reported in Table 1.
The infrared spectra of the synthesized compounds (4ie4v,
4ae4g) showed strong absorption bands at 1745e1687 cm1,d heteroarylazo analogues (4ie4v, 4ae4g) against various fungal
nsc C. glabratad C. neoformanse
J)  p’
value
Mean (IeJ) 
S.E.M
p’
value
Mean (IeJ) 
S.E.M
p’
value
0.65 1.000 3.33  0.76 1.000 2.50  0.61 1.000
0.65 1.000 5.50  0.76 1.000 0.67  0.61 0.527
0.65 1.000 5.83  0.76 1.000 0.67  0.61 0.527
0.65 1.000 6.00  0.76 1.000 2.50  0.61* 0.001
0.65 1.000 5.83  0.76 1.000 0.67  0.61 0.527
0.65 1.000 1.00  0.76 0.999 0.50  0.61 0.657
0.65 1.000 6.00  0.76 1.000 14.17  0.61 1.000
0.65 1.000 5.67  0.76 1.000 3.00  0.61 1.000
0.65 1.000 5.83  0.76 1.000 5.67  0.61 1.000
0.65 1.000 7.00  0.76 1.000 5.50  0.61* 0.000
0.65 1.000 6.17  0.76 1.000 2.00  0.61* 0.008
0.65 1.000 7.00  0.76 1.000 2.17  0.61 1.000
ndard Error Mean (n ¼ 6), *p value<0.05.
Figure 7: Bacteria zone of inhibition showed by 4-HC arylazo analogues: plate-a (4i. 4ii, 4iii, 4iv) against E. coli and plate-b (4i. 4ii, 4iii,
4iv) against S. mitis and 4-HC heteroarylazo analogues plate-c (4d, 4e, 4f, 4g) against V. cholera.
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to the presence of lactone carbonyl (C]Ostr), O-Hstr, C]
Cstr and eN]N-str functional groups, respectively. This
broad value (35553446 cm1) reveals that an enolic hydroxyl
group was involved due to the intermolecular and intra-
molecular hydrogen bonding.14 Compound 4i showed three
strong absorption bands at 1695 cm1, 1300 and 1137 cm1,
which were assigned to the stretching of the coumarin
lactone carbonyl and the asym/sym stretching of the sulfonyl
group, respectively. The medium frequency bands at 1510
and 1280 cm1 were assigned to (eN]Ne) str and C-Ostr,
respectively. Compound 4iv showed four absorption bands
at 1742, 1697, 1609 and 1509 cm1, which were assigned to
the stretching of the carboxylic acid C]O, the carbonyl
group of lactone, the C]C str. of coumarin and eN]Ne,
respectively. A signal attributable to an aryl amine group
was not observed in the 1H NMR spectral data, and amine
absorption bands were also absent in the in FT/IR spectral
data for all compounds. All 1H NMR spectra, except for
those of 4i and 4iv, showed board singlet at d 16.73e
16.85 ppm, which suggests the presence of enolic OH in the
compounds. For compound 4ii, the proton of the eOCH3
group was observed in the H1 NMR at d3.83 ppm as singlet,
and the aromatic protons of coumarin were also observed at
d 6.94e7.34 ppm as a multiplet (Figure 2). In addition, the
three medium absorption bands at 2925, 1264 and
1110 cm1 were assigned to the CH2 str., ]CeOCH3 and
CeO str. of the methoxy group, respectively. Compound 4i
showed two sharp strong vibration bands at 1300 and
1134 cm1 due to SO2 asymmetrical and symmetricalFigure 8: Fungal zone of inhibition showed by 4-HC aryl and hetero ar
(4e, 4f and 4g) against Cryptococcus neoformans.stretching, respectively (Figure 3). In addition, two series of
protons were evident as a multiplet at d 7.75e7.85 and 7.37e
7.81 ppm, which were assigned to the aromatic phenyl
protons and coumarin protons, respectively.
The predicted molecular weights of synthesized com-
pounds were confirmed by LC-MS and provide strong evi-
dence for the molecular formulas of these compounds.
Compounds 4i, 4ii, 4iii, 4iv and 4v had m/z values of 344.96,
296.99, 310.95, 310.33 and 281.13, respectively, which pro-
vides strong evidence for the molecular formulas of these
compounds. The LC-MS of compound 4iv is given in
Figure 4.
Solvatochromic effect on 4-HC arylazo analogues
The solvent effects of the products were studied by UV-
Visible spectrophotometry. The absorption spectra of these
compounds (4ie4v) were observed in different solvents at a
concentration of 105 to 106 M, and the results are reported
in Table 2. Compound 4ii showed highest bathochromic shift
in all solvents with respect to the lmax. The lmax of compound
4ii was 450 nm in methanol. The solvatochromic effect of 4-
HC aryl and hetero aryl analogues in dioxane are reported
in Figure 5. These bathochromic shifts can be attributed to the
interaction of the amino protons in the compounds with polar
aprotic solvents, such as THF, because the polarity of the dyes
generally increases in an excited state. The introduction of an
antipyrinyl substituent to the coumarin nucleus at the C-3
position yielded the largest bathochromic shift (lmax
447 nm) compared with the other hetero-aryl compounds inyl analogues plate-a (4i. 4ii, 4iii, 4iv), plate-b (4v, 4b, 4c, 4a), plate-c
Figure 9: Statistical interpretation of significant antimicrobial ef-
fect of compound 4e with the help of error bars.
J. Sahoo and P. Sudhir Kumar 315all solvents. The presence of a 2-methoxy phenyl (electron
donating substituent) moiety in 4ii attached in the same ring
system resulted in a bathochromic shift in all solvents
compared with the 3-nitro phenyl (electron withdrawing
substituent) of 4iv. The lmax did not appreciably change for
compounds 4i and 4f.
Thermal analysis
The sharp endothermic peak yielded by compound 4i at
207.39 C corresponds to its melting point (Figure 6).
Antimicrobial evaluation
The mean  SD of the zone of inhibition for the newly
synthesized 4-HC aryl and hetero aryl analogues was
compared with that of the standard (RA) for each microbial
strain with a one way-analysis of variance. The mean zone of
inhibition significantly differed by compound, with a p value
of 0.00. The pair-wise comparisons of each newly synthesized
compound with the standard are expressed as the mean
difference  SEM.
The zones of inhibition were tested against E. coli, S.
enterica ser. typhi, S. enterica typhimurium, S. enterica par-
atyphi, S. flexneri, P. aeruginosa, V. cholera, K. pneumoniae,
M. luteus, B. circulans, S. mitis, P. carotovarum, B. subtilis
and S. aureus. The highest mean zones of inhibition (mm) for
these strains observed for compounds 4d, 4e, 4a, 4ii, 4e, 4b,
4e, 4e, 4e, 4iv, 4iv, 4iv, 4e and 4e were 19.00  1.27,
15.50  0.55, 18.17  0.41, 18.33  1.03, 24.50  0.55,
24.00  0.63, 19.83  0.75, 26.50  0.55, 18.50  0.55,
35.50  1.23, 25.17  0.75, 17.50  0.55, 23.00  0.89 and
25.00  0.89, respectively, as presented in Table 3.1.
The pair-wise comparisons of each newly synthesized
compound with the standard revealed that 4iv and 4e
inhibited S. mitis andM. luteus significantly more (p < 0.05)
than RA; whereas compound 4iv was significantly more
active than RA against B. circulans. Compound 4e showed a
significantly larger zone of inhibition than RA against the
bacterial strains S. mitis and M. luteus, S. flexneri, K. pneu-
monia, B. subtilis and S. aureus, as presented in Table 3.2.
The largest mean zones of inhibition (mm) of compounds
4iv (30.00  1.79), 4iii (18.17  0.41), 4f (24.17  0.75), 4a
(18.00  1.27) and 4e (35.00  1.27) were observed against
A. niger, T. rubrum, C. albicans, C. glabrata and
C. neoformans, respectively, as presented in Table 4.1.
The pair-wise comparison of each newly synthesized
4-HC analogues with RA revealed that all compounds except
4c and 4d were significantly more active (p < 0.05) against
A. niger than RA. Moreover, compounds 4iv, 4e and 4f
were significantly more active against the fungal strain
C. neoformans than RA, as reported in Table 4.2.
The zones of inhibition of the 4-HC arylazo analogues
against different microorganisms are reported in Figures 7
and 8, and the significant antimicrobial activity of 4e is
graphically presented in Figure 9.
Evaluation of minimum inhibitory concentration (MIC)
The inhibitory property of the 4-HC analogues was
determined in terms of the MIC (mg ml1) (Table 5). The 4-HC analogues 4ii, 4iv, 4b and 4e exhibited potential anti-
bacterial activity at 31.25 mg ml1 against most bacterial
strains. The 4-HC hetero aryl analogue 4e inhibited the
growth of twelve pathogens at a concentration of
31.25 mg ml1. The 2-methoxy-substituted 4-HC analogue 4ii
was the next most potent compound; it inhibited the growth
of seven bacterial pathogens at a concentration of
31.25 mg ml1. The reference antibiotic (Ampicillin) inhibited
all bacterial strains at 31.25 mg ml1. Thus, 4e and 4ivmay be
considered highly effective, and 4v, 4a, 4b and 4f may be
considered moderately active compounds, which corrobo-
rates the above findings.
Pharmacological evaluations
Acute toxic dose determination
The test compounds were safe at concentrations of up to
2000 mg/kg body weight. No toxic symptoms, gross behav-
ioural changes and mortality were observed.
Table 5: MIC (mg mlL1) values of newly synthesized 4-HC aryl and heteroarylazo analogues (4ie4v, 4ae4g) against various bacterial
strains.
Compd. E. colia S. ser. typhib S. typhimeriumc S. paratyphid S. flexnerie P. aeruginosaf V. cholerag
4i 500 250 250 250 500 31.25 31.25
4ii 62.5 31.25 250 31.25 e 250 125
4iii 31.25 125 125 125 125 250 500
4iv 31.25 62.5 125 62.5 31.25 31.25 125
4v 31.25 125 31.25 125 500 31.25 500
4a 31.25 500 31.25 500 500 62.5 >500
4b 31.25 125 125 125 125 31.25 >500
4c 62.5 500 62.5 500 125 31.25 e
4d 62.5 125 31.25 31.25 500 62.5 500
4e 31.25 31.25 125 31.25 31.25 31.25 31.25
4f e e 500 e 125 62.5 500
4g e 500 500 500 500 500 125
RA 31.25 31.25 31.25 31.25 31.25 31.25 31.25
Compd. K. pneumoniaeh M. luteusi B. circulansj S. mitisk P. carotovaruml B. subtilism S. aureusn
4i e e 125 125 500 125 e
4ii 31.25 250 31.25 31.25 31.25 31.25 250
4iii e 125 500 31.25 125 500 500
4iv 125 31.25 31.25 31.25 125 125 e
4v e 500 31.25 e 125 500 500
4a 500 500 500 500 125 31.25 31.25
4b 31.25 e 125 31.25 125 62.05 31.25
4c e e e e 500 62.05 e
4d 125 125 e 125 500 31.25 31.25
4e 31.25 31.25 31.25 31.25 125 31.25 31.25
4f e 500 e 500 125 >500 31.25
4g 125 125 125 500 125 >500 >500
RA 31.25 31.25 31.25 31.25 31.25 31.25 31.25
e No zone of inhibition.
a Escherichia coli.
b Salmonella enterica ser. typhi.
c Salmonella enterica typhimurium.
d Salmonella enterica paratyphi.
e Shigella flexneri.
f Pseudomonas aeruginosa.
g Vibrio cholera.
h Klebsiella pneumonia.
i Micrococcus luteus.
j Bacillus circulans.
k Streptococcus mitis.
l Pectobacterium carotovorum.
m Bacillus subtilis.
n Staphylococcus aureus.
Table 6: Wound healing activity of some newly synthesized 4-HC aryl and heteroarylazo analogues by excision and incision wound
model.
Compd. Wound contraction (%) Incision wound model
0 Day 4th Day 8th Day 12th Day 16th Day %inhibition Tensile strength(g)
Control 318.1  6.4 237.3  6.5 182.8  5.3 134.3  4.4 82  4.8 74.22 310  7.2
Nitro furazone
(Standard)
326  6.2 201.8  7.7** 123.6  4.5*** 80.1  4.7*** 40  5.6*** 87.73 530  6.8***
4ii (5%) 320.1  5.5 234  7.4 181.6  5.1 130.6  6.2 70.6  5.8 77.94 317  4
4ii (10%) 311.5  5.6 230.6  8.5 177.8  6.5 127.3  5.4 67  4.8 78.49 326  7.6
4iv (5%) 311.3  8.6 213.5  6.7* 160.6  8.8* 107  5.1** 51.3  3.7** 83.52 365  8.5***
4iv (10%) 319  3.1 208.6  8.6* 146.6  5.3** 90.6  5.*** 45  4.8** 85.89 415.5  6.5**
4a (5%) 316.1  6.6 225.1  5 175.3  5.1 126.1  4.7 65.3  6 79.34 323  6.9
4a (10%) 311.5  6.5 224.3  7 168.8  3.7 124.6  5.3 60.1  6* 80.70 333  7.8*
4e (5%) 319.8  3.9 221  6.5 164.3  5.7a 116.6  5.1* 53.5  6.8* 83.27 349  7.9**
4e (10%) 313.3  4.7 214  6.9a* 162.3  7.2* 100.5  4.9*** 60.1  6* 80.81 376  6.5***
Values are expressed in MEAN  S.E.M of six animals. One Way ANOVA followed by Dunnett’s t-test. (F-value denotes statistical
significance at *p < 0.05, **p < 0.01 and ***p < 0.001), respectively, in comparison to group-I.
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Figure 10: Wound treated with 4-HC aryl analogue (4iv) showed progressive healing on 0 day (a), 4th day (b), 12th day (c) and 16th day (d).
J. Sahoo and P. Sudhir Kumar 317Screening of wound healing activity
In the excision wound model, the wounds progressively
contracted until the end of observation on the 16th day.
Optimum healing was defined as a minimum remaining
wound area or % inhibition for the subjected compounds
compared with the standard. The compounds included in the
experiment showed significant wound healing activity, with
more than 80% of wound inhibition by day 16, as reported in
Table 6. The remaining wound areas of the control and
standard were 82  4.8 and 40  5.6 mm2, respectively
with 74.22% and 87.73% inhibition, respectively (Figure 10).
The incision study revealed that compounds 4iv, 4a and 4e
showed significant breaking strength (force responsible for
opening of the closed wound) more than the control
(Table 6).Table 7: Antioxidant activity of newly synthesized 4-HC aryl and he
Conc. mgml1 10 50
Compound % Inhibition
4ii 43  0.88 50  0.75
4iii 46  0.78 57  0.67
4iv 48  0.67 58  0.67
4a 41  0.75 56  0.67
BHT 42  0.86 57  0.67
Conc. mgml1 2 4 6
Compound % Inhibition
4b 5  0.78 19  0.88 31 
4c 11  0.75 19  0.67 37 
4e 8  0.78 19  0.86 30 
4g 4  0.88 13  0.75 25 
Free radical scavenging activity showed the results of % inhibition andIn vitro antioxidant screening
DPPH radicals accept a hydrogen atom or electron from
organic molecules and can form stable diamagnetic mole-
cules. The scavenging effects of newly synthesized com-
pounds 4ii, 4iii, 4iv, 4a, 4b, 4c, 4e and 4g as well as that of the
butylated hydroxy toluene standard were examined. The
50% of inhibition (IC50) concentrations of the newly syn-
thesized compounds were 50  0.88, 22  0.75, 20  0.5,
30  0.78, 9  0.97, 7  0.84, 9  0.87 and 10  0.94 mg/ml,
respectively, whereas that of BHT was 32  0.4 mg/ml
(Table 7). The antioxidant activities of the synthesized
analogues are reported in Figure 11. The study reveals that
the presence of electron withdrawing groups (eCOOH,
NO2) increases the antioxidant potential, which may beteroarylazo analogues.
100 200 IC50
56  0.78 63  0.67 50  0.88
67  0.86 79  0.75 22  0.75
69  0.78 80  0.75 20  0.5
61  0.88 78  0.78 30  0.78
72  0.78 97  0.69 32  0.4
8 10 IC50
0.75 45  0.67 58  0.67 9  0.97
0.88 59  0.86 72  0.78 7  0.84
0.86 41  0.75 59  0.67 9  0.87
0.67 35  0.78 52  0.67 10  0.94
(IC50). IC50 expressed mean  SD (n ¼ 3).
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hydroxyl group of 4-HC associated with the negative
inductive effect of these groups. The positive charge inten-
sification may lead to free radical inhibition. Moreover, the
substitution electron-accepting groups are good free radical
quenchers. The substitution of an electron-releasing group
(eOCH3) was found to decrease the free radical scavenging
activity, which may be due to a positive inductive effect.Figure 11: Graphical interpretation of radical scavenging activity
of 4-HC analogues (compounds against IC50).Discussion
All newly synthesized compounds exhibited good anti-
microbial activity against most strains. However, the 4-HC
arylazo analogue 4iv exhibited significant antibacterial and
antifungal activity, which may be due to nitro substitution.18
The presence of N-alkyl substituted pyrazolone 4e derived
from 4-HC may be responsible for the excellent antimicro-
bial and antioxidant activity.
Based on the antimicrobial screening, five (4ii, 4iii, 4iv, 4a
and 4e) out of twelve (4ie4v, 4ae4g earlier reported) newly
synthesized 4-HC analogues showed maximum activity
against pathogenic bacterial strains. The wound healing ac-
tivity of the most potent four compounds (4ii, 4iv, 4a and 4e)
was evaluated with an excision and incision model. The
reactive oxygen species secreted at wound site are responsible
for delayed healing.19 Moreover, invading microorganisms
and free radicals20 also prevent healing. Antioxidants
terminate the formation of free radical intermediates and
enable quick recovery of the wound and thus help prevent
cell mortality.21 Our synthesized compounds showed
excellent antimicrobial activity and significant antioxidant
potential in the wound healing study.
Conclusions
This research details an interesting, easily executed and
simple technique for a one step synthesis of coumarin ana-
logues to provide bioactive molecules that inhibit against
various pathogens. The synthesized compounds were suc-
cessfully characterized, and their in vitro antimicrobial and
antioxidant activities were explored such that they can be
used as ligands for new azo-metal complexes.
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